Table 6 Univariate analysis for the influence of candidate contributing factors.
∆L | ∆D | |||
|---|---|---|---|---|
Mean ± SD (mm) | P | Mean ± SD (mm) | P | |
Gender | ||||
Male | −1.60 ± 1.61 | 0.005 * | 1.80 ± 1.47 | <0.001 * |
Female | −0.95 ± 1.24 | 0.93 ± 1.42 | ||
Age (y) | ||||
<15 | −1.64 ± 1.30 | <0.001 * | 1.81 ± 1.47 | <0.001 * |
15 ≤ age<22 | −1.02 ± 1.17 | 0.90 ± 1.19 | ||
≥ 22 | −0.63 ± 1.42 | 0.67 ± 1.55 | ||
Follow-up period (m) | ||||
3 ≤ F ≤ 6 | −1.19 ± 1.38 | 0.645 | 1.14 ± 1.19 | 0.272 |
6 < F ≤ 12 | −1.01 ± 1.27 | 1.09 ± 1.62 | ||
>12 | −1.11 ± 1.61 | 1.13 ± 1.42 | ||
Disc morphology | ||||
Type I | −0.98 ± 1.37 | 0.006 * | .97 ± 1.36 | <0.001 * |
Type II | −1.36 ± 1.52 | 1.48 ± 1.63 | ||
Type III | −1.27 ± 1.10 | 1.39 ± 1.40 | ||
Type IV | −0.47 ± 0.73 | 0.16 ± 0.71 | ||
Type V | 0.03 ± 0.49 | −0.40 ± 0.94 | ||
Wilkes stages | ||||
Stage I | −0.62 ± 0.86 | <0.001 * | 0.83 ± 1.27 | 0.046 * |
Stage II | −0.79 ± 1.32 | 0.80 ± 1.31 | ||
Stage III | −1.58 ± 1.47 | 1.42 ± 1.52 | ||
Stage IV | −0.74 ± 1.33 | 1.01 ± 1.62 | ||
Stage V | 0.22 ± 0.77 | −0.18 ± 0.16 | ||
Joint effusion | ||||
Absent | −0.93 ± 1.25 | <0.001 * | 0.98 ± 1.43 | 0.001 * |
Present | −2.04 ± 1.52 | 1.90 ± 1.51 | ||